Hydroxamic and carboxylic acid derivatives
CA 2317455 C · Owner: Owen, David Alan · Inventors: Montana, John Gary; Owen, David Alan; Baxter, Andrew Douglas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
For the treatment of cancer, inflammation and other conditions associated with matrix metalloproteinases or that are mediated by TNF .alpha. or enzymes involved in the shedding of L-selectin CD23, the TNF receptors, IL-1 , receptors or IL-6 receptors compounds are of general formula (I) B-X-(CH2)m- (CR1R2)n-W-COY.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 29, 1999 and granted January 25, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 29, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 29, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.